March 30, 2022，TenNor Therapeutics (Suzhou) Limited announced the completion of 264 million RMB series D financing, led jointly by Yanchuang Capital and GTJA Investment, followed by Galaxy Capital, Bison Capital, Guolian Xinchuang, Zhongnuo Venture Capital and Oriza Holdings. The capital raised will be used to advance late-stage clinical development of key products.

TenNor Therapeutics is a clinical stage, global new drug research and development company. The product portfolio is mainly focused in disease areas related to bacterial infection and dysbacteriosis with major unmet medical needs. TenNor has completed phase II clinical trials in multiple indications of three key products and is initiating phase III multiregional clinical trials (MRCT). The target indications include implantable medical devices infection, Helicobacter pylori infection, cirrhotic hepatic encephalopathy and diarrhea-predominant irritable bowel syndrome to address the unmet needs in these areas. TenNor has the worldwide intellectual property rights for these products.

"The series D financing will help TenNor to advance its key products into phase III clinical trials. We are very pleased to complete this round of financing under the current investment environment and sincerely thank series D investors for their recognition and support of TenNor Therapeutics." Dr. Zhenkun Ma, founder and CEO of TenNor Therapeutics, said, "We will continue to follow the unmet need based, science drive new drug development strategy, rapidly advance our new drug development portfolio and bring new drug products to patients as soon as possible."

Ms. Liu Zeng, President of Yanchuang Capital, said: "We are pleased to have the opportunity to participate in series D financing of TenNor Therapeutics. TenNor has an global new drug research and development team. After many years of hard work, it has developed a differentiated new drug pipeline in disease area associated with bacterial infection and dysbacteriosis. Multiple products have begun to enter phase III clinical trials. We look forward to further collaborating with the TenNor team to help TenNor advance its product portfolio and bring valuable treatment options to patients as soon as possible."

Mr. Yu Jianlin, managing partner of GTJA Investment, said: "TenNor Therapeutics is a leading enterprise in disease area associated with bacterial infection and dysbacteriosis. We are optimistic about TenNor’s unique product portfolio and market potential. We are very pleased to participate in this round of financing to help TenNor to advance its key products into phase III clinical trials. We will continuous to help the company by utilizing the industry resources of GTJA in human health area. We look forward to and firmly believe that TenNor will become the leading new drug R&D company in infectious disease area in the world. "

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late stage of clinical development, targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com